Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Glucotrack, Inc.GCTK · Entity 8422 | Director | March 25, 2025 | October 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Glucotrack, Inc.
Report date March 25, 2025 · Filed October 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 2,148 |
Ending reported balance
After 2025-10-03 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-03-25 · Grant · Acquired 32 · Balance 762 Row 2 · 2025-07-11 · Grant · Acquired 1,000 · Balance 1,762 Row 3 · 2025-10-03 · Grant · Acquired 386 · Balance 2,148 |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.40 · Expires 2035-10-03 | Direct | 4,055 |
Reported balance
After 2025-10-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-03 · Grant · Acquired 4,055 · Balance 4,055 F1: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2025 Filed Oct 7, 2025 20:58 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantStock option (right to buy) · Derivative | 4,055 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001993078-25-000003 · primary_doc.xml · derivative · entry 4 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,055 Underlying: Common Stock, par value $0.001 per share · 4,055 shares Expires 2035-10-03 F1 · derivative.exercise_date: Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date. Read SEC document |
| October 03, 2025 Filed Oct 7, 2025 20:58 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 386 | $0.00 | $0.00 |
DisclosureSEC source: 0001993078-25-000003 · primary_doc.xml · nonDerivative · entry 3 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,148 Read SEC document |
| July 11, 2025 Filed Oct 7, 2025 20:58 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001993078-25-000003 · primary_doc.xml · nonDerivative · entry 2 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,762 Read SEC document |
| March 26, 2025 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 1,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · nonDerivative · entry 5 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,632 Read SEC document |
| March 25, 2025 Filed Oct 7, 2025 20:58 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 32 | $0.00 | $0.00 |
DisclosureSEC source: 0001993078-25-000003 · primary_doc.xml · nonDerivative · entry 1 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 762 Read SEC document |
| March 12, 2025 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | OtherSeries B Common Warrant · Derivative | 2,078 | $0.00 | $0.00 |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · derivative · entry 10 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 40,297 shares Expires 2027-07-03 F4 · derivative.exercise_price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise"). F5 · derivative.exercise_price: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock. F5 · kind: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock. Read SEC document |
| March 12, 2025 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | OtherCommon Stock, par value $0.001 per share | 40,297 | $0.00 | $0.00 |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · nonDerivative · entry 4 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,736 F5 · kind: On March 12, 2025, the reporting person effected an Alternative Cashless Exercise of the Series B Common Warrants and exercised the warrants on a cashless basis via a warrant exchange for 15,435 shares of Common Stock. Read SEC document |
| November 14, 2024 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantSeries B Common Warrant · Derivative | 2,078 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · derivative · entry 9 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,078 Underlying: Common Stock, par value $0.001 per share · 40,297 shares Expires 2027-07-03 F4 · derivative.exercise_price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise"). F4 · price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise"). Read SEC document |
| November 14, 2024 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantSeries A Common Warrant · Derivative | 2,078 | Not disclosed Strike: $5.60 | Not disclosed |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · derivative · entry 8 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,078 Underlying: Common Stock, par value $0.001 per share · 2,078 shares Expires 2030-01-03 F4 · price: On November 14, 2024, in connection with the conversion of the Note, the reporting person was issued Series A common warrants (the "Series A Common Warrants") to purchase Common Stock and Series B common warrants (the "Series B Common Warrants") to purchase Common Stock, each with an exercise price of $5.60 per share; provided that, at any time while the Series B Common Warrants are outstanding, the holder could exercise the Series B Common Warrants on a cashless basis pursuant to an alternate cashless exercise option, pursuant to which the holder of the Series B Common Warrant had the right to receive an aggregate number of shares of Common Stock equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cash exercise rather than a cashless exercise of the Series B Common Warrant and (ii) 3.0 (the "Alternative Cashless Exercise"). Read SEC document |
| November 14, 2024 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | ConversionConvertible Promissory Note · Derivative | Not disclosed | $64,831.00 Strike: $31.20 | $64,831.00 |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · derivative · entry 7 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.001 per share · 2,078 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into common stock, par value $0.001 per share (the "Common Stock") at the Floor Price. F1 · derivative.exercise_date: On July 18, 2024, the reporting person purchased a convertible promissory note in the principal amount of $50,000 (the "Note"). The Note bears simple interest at the rate of eight percent (8%) per annum and is due and payable in cash on the earlier of: (a) the twelve (12) month anniversary of Note, or (b) the date of closing of a Qualified Financing (defined below) (the "Maturity Date"). F2 · derivative.exercise_date: If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Note (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $500,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $31.20 (the "Floor Price"). F1 · derivative.expiration_date: On July 18, 2024, the reporting person purchased a convertible promissory note in the principal amount of $50,000 (the "Note"). The Note bears simple interest at the rate of eight percent (8%) per annum and is due and payable in cash on the earlier of: (a) the twelve (12) month anniversary of Note, or (b) the date of closing of a Qualified Financing (defined below) (the "Maturity Date"). F2 · derivative.expiration_date: If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Note (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $500,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $31.20 (the "Floor Price"). Read SEC document |
| November 14, 2024 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | ConversionCommon Stock, par value $0.001 per share | 2,078 | $31.20 | $64,833.60 |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · nonDerivative · entry 3 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: On November 14, 2024, the issuer completed a Qualified Financing and all outstanding principal and accrued but unpaid interest on the Note converted into common stock, par value $0.001 per share (the "Common Stock") at the Floor Price. Read SEC document |
| July 18, 2024 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | PurchaseConvertible Promissory Note · Derivative | Not disclosed | $50,000.00 Strike: $31.20 | $50,000.00 |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · derivative · entry 6 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock, par value $0.001 per share · 1,603 shares Expires not disclosed F1 · derivative.exercise_date: On July 18, 2024, the reporting person purchased a convertible promissory note in the principal amount of $50,000 (the "Note"). The Note bears simple interest at the rate of eight percent (8%) per annum and is due and payable in cash on the earlier of: (a) the twelve (12) month anniversary of Note, or (b) the date of closing of a Qualified Financing (defined below) (the "Maturity Date"). F2 · derivative.exercise_date: If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Note (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $500,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $31.20 (the "Floor Price"). F1 · derivative.expiration_date: On July 18, 2024, the reporting person purchased a convertible promissory note in the principal amount of $50,000 (the "Note"). The Note bears simple interest at the rate of eight percent (8%) per annum and is due and payable in cash on the earlier of: (a) the twelve (12) month anniversary of Note, or (b) the date of closing of a Qualified Financing (defined below) (the "Maturity Date"). F2 · derivative.expiration_date: If not sooner repaid, all outstanding principal and accrued but unpaid interest on the Note (the "Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least $500,000 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than $31.20 (the "Floor Price"). Read SEC document |
| April 08, 2024 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 458 | $0.00 | $0.00 |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · nonDerivative · entry 2 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,361 Read SEC document |
| December 31, 2023 Filed Mar 31, 2025 07:52 UTC | Glucotrack, Inc. GCTK · Entity 8422 | GrantCommon Stock, par value $0.001 per share | 903 | $0.00 | $0.00 |
DisclosureSEC source: 0001474506-25-000070 · primary_doc.xml · nonDerivative · entry 1 Carter Erin Catherine · CIK 0001993078 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.